Renaissance Capital logo

XGN News

US IPO Weekly Recap: Health and tech shine as week’s 5 IPOs close Friday up 20% or more

DDOG

Five health and tech companies went public this week, and each finished the week up at least 20%. One SPAC also IPO'd. Three companies and one SPAC submitted initial filings. After weeks of nonstop news coverage, The We Company (WE) delayed its IPO to the 4Q19. Another mega IPO, Airbnb, announced it would seek public markets in 2020. The leader of the pack was...read more

Diagnostics provider Exagen prices $50 million IPO at $14, the low end of the range

XGN

Exagen, which sells blood tests that can diagnose, prognose, or monitor autoimmune diseases, raised $50 million by offering 3.6 million shares at $14, the low end of the range of $14 to $16. The company offered an additional 266,667 shares to maintain its deal size. Exagen plans to list on the Nasdaq under the symbol XGN. Cowen, Cantor Fitzgerald and William Blair acted as...read more

US IPO Week Ahead: Datadog chases $7 billion valuation in 5-IPO week

Five IPOs and one SPAC plan to raise $1.7 billion in the week ahead. Rumors are swirling that The We Company (WE) will launch its long-awaited IPO.  Datadog (DDOG) will join the year's growing list of VC-backed tech companies going public at $5+ billion market caps (UBER, LYFT, WORK, PINS, CRWD). The company targets $492...read more

Diagnostic test maker Exagen sets terms for $50 million IPO

XGN

Exagen, which sells blood tests that can diagnose, prognose, or monitor autoimmune diseases, announced terms for its IPO on Monday. The Vista, CA-based company plans to raise $50 million by offering 3.3 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Exagen would command a fully diluted market value of $190 million. Exagen was founded...read more